UNSPSC 51273008: Piperocaine

This classification denotes an anesthetic agent with the molecular formula C16H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F66XUI6GZL, chemically known as 2-methyl-1-piperidinopropanol, benzoate but generally known as piperocaine, which bears US NIH Compound Identifier 10782. European Medicines Agency schedules Piperocaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09871MIG. The term PIPEROCAINE is an International Non-Proprietary Name.

UNSPSC 51273008 Piperocaine is a Commodity code that nominally covers a specific injectable local anesthetic, but recent state and local procurement activity under this code does not reflect demand for piperocaine itself. Instead, the opportunities tagged to this code involve procurement of naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription fulfillment programs. The mismatch between the code's narrow pharmaceutical scope and the actual procurements suggests either that state and local agencies are using this code as a catch-all for pharmaceutical and medical supply acquisitions outside traditional therapeutic classifications, or that the tagging does not reflect the true nature of the work being solicited. State and local issuing bodies under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state, local, and regional jurisdictions in Minnesota and Oregon).

Recent representative opportunities span naloxone procurement, generic pharmaceutical contracting, and pharmacy benefit program design. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, with a due date of July 26, 2023 (note: date inconsistency in source). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Activity concentrates in Florida, Texas, and Minnesota–Oregon, though the code shows limited recent volume and no clarity on whether it reflects genuine demand for piperocaine or represents a data classification error.